Andrew McGarry, MD
Neurology · Cherry Hill, NJNPI 1902818610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,675 of the $14,219 with a category attached, or 96.2%. UCB SA accounts for 68.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $8,110 and has fallen 98.5% since, to $122 in 2025.
Across 41 payments — averaging $346.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$10K
- Jazz Pharmaceuticals Inc.$4K
- Acadia Pharmaceuticals Inc$170
- Teva Pharmaceuticals USA, Inc.$99
- AbbVie$64
- Medtronic$52
- plus $99 from 4 others
Across 13 payments — averaging $602.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$5K
- Ipsen Innovation$2K
- Acadia Pharmaceuticals Inc$1K
What the payments were for
- Consulting fees$13,67596%
- Speaking & faculty fees$130%
- Travel & lodging$600%
- Food & beverage$2162%
- Education$2552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 5 | $9,675 |
| Jazz Pharmaceuticals Inc. | 2 | $4,060 |
| Acadia Pharmaceuticals Inc | 20 | $170 |
| Teva Pharmaceuticals USA, Inc. | 1 | $99 |
| AbbVie | 4 | $64 |
| Medtronic | 3 | $52 |
| Philips North America LLC | 3 | $48 |
| Biomerieux Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $13 |
How this compares
$14,219 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $267,712 |
| NuplazidPimavanserin Tartrate | 47 | $247,573 |
| RytaryCarbidopa/Levodopa | 83 | $171,393 |
| NourianzIstradefylline | 46 | $143,529 |
| NeuproRotigotine | 68 | $103,773 |
| InbrijaLevodopa | 23 | $85,580 |
| IngrezzaValbenazine Tosylate | 11 | $84,476 |
| Tetrabenazine | 28 | $39,749 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 511 | $21,561 |
| Ropinirole ErRopinirole Hcl | 86 | $15,767 |
| Rasagiline Mesylate | 49 | $13,569 |
| Droxidopa | 11 | $12,518 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 15 | $11,413 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 168 | $8,276 |
| Carbidopa | 21 | $7,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $99 | $267,71212 claims |
| Acadia Pharmaceuticals IncNuplazid | $170 | $247,57347 claims |
| Acorda Therapeutics, IncInbrija | $13 | $85,58023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.
Other neurology in Cherry Hill
- Keith PreisCherry Hill$36K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.